People · Operator
Named in public records as an officer, director or promoter · active 2011–2017 · Biotechnology, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avalyn Pharma Inc. | — | Biotechnology | Series D+ | $244.0M | $2.7B | 2011 |
| Suneva Medical, Inc. | — | Healthtech | Series B | $140.2M | $24.9M | 2016 |
| Sorrento Therapeutics, Inc. | — | Biotechnology | Series A | $19.8M | $66.9M | 2011 |
Richard G Vincent at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard G Vincent on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Barton Hutt | 1 | 14 |
| Jonathan Leff | 1 | 11 |
| Ketan Patel | 1 | 10 |
| Brian Chee | 1 | 10 |
| Tiba Aynechi | 1 | 9 |
| Niall O'Donnell | 1 | 7 |
| Peter Moldt | 1 | 6 |
| Dennis Condon | 1 | 5 |
| Antonius Schuh | 1 | 5 |
| Henry Ji | 1 | 5 |
| Lewis J. Shuster | 1 | 4 |
| Curtis Lockshin | 1 | 3 |
| Todd C. Davis | 1 | 3 |
| Michael Brower | 1 | 3 |
| A. Bruce Montgomery | 1 | 3 |
| Daniel D. Burgess | 1 | 3 |
| Todd Harris | 1 | 3 |
| Glenn L. Halpryn | 1 | 3 |
| Michael J. Kamdar | 1 | 3 |
| M. Scott Salka | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.